Compare SI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SI | CCCC |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 404.7M |
| IPO Year | 2025 | 2020 |
| Metric | SI | CCCC |
|---|---|---|
| Price | $17.60 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $20.80 | $12.20 |
| AVG Volume (30 Days) | 77.9K | ★ 1.8M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,317,000.00 | $35,947,000.00 |
| Revenue This Year | $39.59 | N/A |
| Revenue Next Year | $31.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.63 | 1.02 |
| 52 Week Low | $10.92 | $1.69 |
| 52 Week High | $24.60 | $5.17 |
| Indicator | SI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 38.87 |
| Support Level | $12.42 | $3.38 |
| Resistance Level | $23.08 | $3.91 |
| Average True Range (ATR) | 0.99 | 0.16 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 10.30 | 16.97 |
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.